Last update Nov. 3, 2018


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a derivative of nitrofuran with antiprotozoal and antibacterial activity.
Indicated in the treatment of giardiasis and cholera. In other types of gastroenteritis antibiotic treatment is not usually indicated. It is also used in the treatment of peptic ulcer caused by Helicobacter pylori.
Oral administration 4 times a day for 2 to 5 days or a maximum of 7 to 10 days in Giardia lamblia infestation.

Since the last update we have not found published data on its excretion in breastmilk.

Little is known of this drug’s pharmacokinetic data in humans.
There is controversy about its oral bioavailability. Although it is believed that it exerts its effect locally in the intestine without being absorbed (Kumar 1995, Valadez 1989), there are authors who have recorded 65% absorption (Calafatti 2001 -> White 1989).

Side effects are rare and mild, usually nausea/vomiting (Altamirano 1989). Although its properties as a monoamine oxidase inhibitor (MAOI) are known, no adverse neurological reactions due to the isolated use of this drug have been recorded (Karamanakos 2008, Bettinger 1968).

Its use is authorized in infants from the one month old (Induquímica 2018, RxList 2004, 1995).

Do not use if there is a history of glucose-6-phosphate dehydrogenase deficiency, in order to avoid risk of hemolysis (Induquímica 2018, RxList 2004, 1995).

Some authors discourage its use during breastfeeding (Mahadevan 2006). Other authors and the manufacturer only advise against its use in mothers with infants younger than one month (Induquímica 2018, 1995).

One mother told us in 2018 that after taking 4 doses of 100 mg of furazolidone along with famotidine, over 24 hours she noticed more drowsiness than usual in her 13-week-old breastfeeding daughter, returning to normal within 48 hours of stopping the medication.


  • Metronidazole (Safe substance and/or breastfeeding is the best option.)
  • Nitazoxanide (Safe substance and/or breastfeeding is the best option.)
  • Tinidazole (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

فورازوليدون is Furazolidone in Arabic.

Is written in other languages:

فورازوليدون is also known as


فورازوليدون belongs to this group or family:


Main tradenames from several countries containing فورازوليدون in its composition:


Variable Value Unit
Oral Bioavail. 5 - 65 %
Molecular weight 225 daltons
Tmax 2.4 hours
3.9 - 4.9 hours


  1. Induquímica. Furazolidona. Acceso online en 2018 Full text (in our servers)
  2. Karamanakos PN. Furazolidone and serotonin syndrome: is there any association? Clinics (Sao Paulo). 2008 Abstract
  3. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)
  4. RxList. Furazolidone (Furoxone). Drug Summary. 2004 Full text (in our servers)
  5. Calafatti SA, Ortiz RA, Deguer M, Martinez M, Pedrazzoli J Jr. Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers. Br J Clin Pharmacol. 2001 Abstract
  6. Furazolidone. 1995 Full text (in our servers)
  7. Kumar AS, Legori M, Sathy N, Mathew R. Furazolidone in typhoid fever--correlation of clinical efficacy with serum bactericidal activity. Indian Pediatr. 1995 Abstract
  8. Valadez-Salazar A, Guiscafre-Gallardo H, Sanchez-Garcia S, Muñoz O. Detection of furazolidone in human biological fluids by high performance liquid chromatography. J Antimicrob Chemother. 1989 Abstract
  9. White AH. Absorption, distribution, metabolism, and excretion of furazolidone. A review of the literature. Scand J Gastroenterol Suppl. 1989 Abstract
  10. Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl. 1989 Abstract
  11. Pettinger WA, Soyangco FG, Oates JA. Inhibition of monoamine oxidase in man by furazolidone. Clin Pharmacol Ther. 1968 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM